bioAffinity Technologies Closes $4M Stock Offering via WallachBeth

WallachBeth Capital LLC, a Jersey City-based capital markets and institutional execution firm, announced the successful closing of a $4 million registered direct offering of common stock for bioAffinity Technologies, Inc., a Nasdaq-listed biotechnology company focused on noninvasive healthcare diagnostics.

The transaction included a concurrent private placement and was priced at-the-market under Nasdaq rules, a structure commonly used by smaller public companies seeking to raise capital without triggering the shareholder approval requirements that apply to below-market offerings.

Read more Retail Investing Platforms Top 41 Million Accounts in Record Quarter →

bioAffinity Technologies, which trades on Nasdaq under the tickers BIAF and BIAFW, develops noninvasive solutions aimed at improving early detection and healthcare outcomes. The fresh capital is expected to support ongoing research and operational needs, though the company did not specify individual allocation targets in the announcement.

Registered direct offerings paired with concurrent private placements have become a frequently used fundraising mechanism among small-cap biotech firms, allowing them to access institutional capital quickly while maintaining compliance with exchange listing standards. WallachBeth Capital served as the exclusive placement agent for the deal.

Continue reading at Banking & Financial Services.